Bristol-Myers Squibb Company (BMY) | |||
---|---|---|---|
54.23 0.98 (1.84%) | 03-28 16:00 | ||
Open: | 53.39 | Pre. Close: | 53.25 |
High: | 54.475 | Low: | 53.39 |
Volume: | 9,401,351 | Market Cap: | 109,663(M) |
Stock Technical Analysis | |
---|---|
Overall: | |
Target: | Six months: 64.29 One year: 75.09 |
Support: | Support1: 52.02 Support2: 50.15 |
Resistance: | Resistance1: 55.04 Resistance2: 64.29 |
Pivot: | 52.74 |
Moving Averages: | MA(5): 52.84 MA(20): 52.57 MA(100): 50.85 MA(250): 58.01 |
MACD: | MACD(12,26): 0.54 Signal(12,26,9): 0.50 |
%K %D: | %K(14,3): 55.00 %D(3): 41.74 |
RSI: | RSI(14): 67.21 |
52-Week: | High: 71.07 Low: 47.58 Change(%): -20.5 |
Average Vol(K): | 3-Month: 16788 10-Days: 23835 |
Prices Prediction (Update @5:00pm) | ||
---|---|---|
If tomorrow: | Open lower | Open higher |
High: | 54.503 - 54.664 | 54.664 - 54.844 |
Low: | 52.897 - 53.095 | 53.095 - 53.317 |
Close: | 53.879 - 54.179 | 54.179 - 54.516 |
Price, MAs and Bollinger Bands |
---|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BMY ] has closed below upper band by 12.0%. Bollinger Bands are 2.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
Company profile |
---|
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York. |
Stock chart |
---|
Financial Analysis | |
---|---|
Price to Book Value: | Outperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
Price to Earnings: | Outperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
Discounted cash flow: | Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
Return on Assets: | Outperform |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
Return on Equity: | Outperform |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
Debt to Equity: | Outperform |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Stock Basics & Statistics | |
---|---|
Exchange: New York Stock Exchange | |
Sector: Healthcare | |
Industry: Drug Manufacturers - General | |
Shares Out. (M) | 2020.00 |
Shares Float (M) | 2020.00 |
% Held by Insiders | 0.10 |
% Held by Institutions | 79.18 |
Shares Short (K) | 32650 |
Shares Short Prior Month (K) | 31090 |
Stock Financials | |
---|---|
EPS | 3.860 |
Book Value (p.s.) | 14.560 |
Profit Margin | 17.83 |
Operating Margin | 17.01 |
Return on Assets (ttm) | 5.6 |
Return on Equity (ttm) | 26.5 |
Qtrly Rev. Growth | 0.6 |
Gross Profit (p.s.) | |
Sales Per Share | 22.282 |
EBITDA (p.s.) | 9.119 |
Qtrly Earnings Growth | -8.90 |
Operating Cash Flow (M) | 13860.00 |
Levered Free Cash Flow (M) | 13780.00 |
Stock Valuation | |
---|---|
PE Ratio | 14.05 |
PEG Ratio | -2.70 |
Price to Book value | 3.72 |
Price to Sales | 2.43 |
Price to Cash Flow | 7.90 |
Stock Dividends | |
---|---|
Dividend | |
Dividend Yield | |
Dividend Growth |